

# NCRO HIGHLIGHTS

**Duke  
Neuroscience**

## Neuroscience Clinical Research Organization

Division of Neurology  
Department of Medicine  
Duke University Health System



*The mission of the NCRO is to foster the development of a world-class neuroscience clinical trials center.*

*February 2006*

### Who's Who in the NCRO

Management	Coordination	Email:
Mark Stacy, Medical Director	Kate Beck 668-2278	<a href="mailto:beck0002@mc.duke.edu">beck0002@mc.duke.edu</a>
Carmelo Graffagnino, Co-Medical Director	Gail Cook 684-0865	<a href="mailto:cook0007@mc.duke.edu">cook0007@mc.duke.edu</a>
Ron Beauvais, Administrator	Joanne Field 668-2842	<a href="mailto:joanne.field@duke.edu">joanne.field@duke.edu</a>
Donna Carnes, Regulatory Assistant	Karen Grace 668-2844	<a href="mailto:karen.grace@duke.edu">karen.grace@duke.edu</a>
Lisa Gauger, Clinical Research Administrator	Debra Heydt 668-2843	<a href="mailto:debra.heydt@duke.edu">debra.heydt@duke.edu</a>
JoAnn Jones, Regulatory Administrator	Rene Link 970-1648	<a href="mailto:link0002@mc.duke.edu">link0002@mc.duke.edu</a>
	Sarah Wyne 668-2837	<a href="mailto:wyn0001@mc.duke.edu">wyn0001@mc.duke.edu</a>

**We would like your suggestions for topics in future issues of the NCRO Newsletter! Please send your suggestions to: JoAnn Jones @ [jones018@mc.duke.edu](mailto:jones018@mc.duke.edu).**

### ACTIVE ENROLLING STUDIES

The NCRO currently supports **40** active studies. This list includes only those studies that are actively enrolling. Please help us reach our targets (column 6).

#### DEMENTIA STUDIES

PI	SPONSOR	INDICATION	STUDY-ID	COORDINATOR	TARGET / # PTS ENROLLED-2/28//06
BURKE, Jim	GlaxoSmithKline	Mild to Moderate AD	Rosiglitazone XR	Heydt 668-2843	15 / 10
WHITE, Heidi	NIH	Mild cog. Impairment	Nicotine Tr of MCI	Cook 684-0865	25 / 15

#### MOVEMENT DISORDERS

MORGENLANDER, J	Private Investors	Restless Legs	RLS	N/A	20 / 16
SCOTT, Burt	Physician Funded	Movement disorder	Visual Documentation	N/A	No Target / 499
SCOTT, Burt	Physician Funded	Movement disorder	Tetrabenazine	N/A	No Target / 63
SCOTT, Burt	Boston Life Sciences	Tremor	Altropane	Wyne 668-2837	20 / 11
SCOTT, Burt	Teva Pharmaceuticals	Early PD	Rasagiline (Adagio)	Field 668-2842	8-10 / 0
STACY, Mark	Novartis	PD requiring levodopa	Stride PD (Stalevo)	Beck 668-2278	15 / 18
STACY, Mark	Inst Neurodeg Disorder	Early PD	SPECT imaging	Gauger 668-1538	8 / 3
STACY, Mark	Ovation Pharmaceuticals	Psychosis in PD	Melperone OV-1003	Gauger 668-1538	6 / 0

#### NEUROMUSCULAR

BEDLACK, Rick	NEALS/CytRx Corp.	ALS	Arimoclomol	Grace 668-2844	10 / 9
---------------	-------------------	-----	-------------	----------------	--------

#### VASCULAR

GOLDSTEIN, Larry	AGA Med Corp	Cryptogenic stroke	RESPECT	Link 970-1648	10 / 17
GOLDSTEIN, Larry	Boehringer Ingelheim	Recurrent strokes	PRoFESS	Link 970-1648	30 / 12
GRAFFAGNINO, C	NIH / Wash Univ	Carotid occlusion	Surgery vs stan med care	Stoner 668-5275	30 / 0
GRAFFAGNINO, C	AstraZeneca-	Acute ischemic stroke	Stroke-SA-NXY-0007	Stoner 668-5275	10 / 10
GRAFFAGNINO, C	Novo Nordisk	Acute intracerebral hemorrhage	F7ICH-1641	Stoner 668-5275	5 / 1
LASKOWITZ, Danny	Biosite	Biomarker-brain injury	Triage Stoke Panel	B. Blessing 970-4888	450 / 584
LASKOWITZ, Danny	Merck & Phys Funded	Aneurismal SAH	Simvastatin-SAH	B. Blessing 970-4888	120 / 51
LYNCH, John	Physician Funded	Traumatic brain injury	Simvastatin-TBI	B. Blessing 970-4888	100 / 6

\*\*\*\*STUDY SPOTLIGHT\*\*\*\*

**New Approved Study Ready for Recruitment!!**  
Please see further details below– Thank you for your Support!

**B. Scott (PI) – ADAGIO**

**“A Multicenter, Double-Blind, Randomized Start, Placebo-Controlled, Parallel-Group Study to Assess Rasagiline as a Disease Modifying Therapy in Early Parkinson’s Disease Subjects”**

The primary objective of this study is to assess rasagiline as a disease modifying therapy in very early phase subjects with idiopathic Parkinson’s Disease (PD) who have not developed sufficient disability to require any anti-PD therapy. The study will consist of two phases: Phase I (36 week double-blind, placebo-controlled phase) followed by Phase II (36 week double-blind, active treatment phase). We expect to recruit 8-10 subjects here at DUHS. Minimum PHI used for screening includes: gender, DOB, diagnosis, medications, medical and social histories. Contact Dr. Burt Scott or Joanne Field (668-2842) if you have a patient who may be interested in this study.

**Duke University School of Medicine  
Clinical Trials Quality Assurance (CTQA)  
LUNCH AND LEARN SERIES  
2005/2006 Schedule**

The lunch and learn series are one hour **coordinator centric educational sessions** with the primary goal of providing useful, hands on knowledge to build a stronger research work force. These sessions will also provide the members of the CTQA office an opportunity to present themselves as a resource to the research community.

<b>March 20</b>	<b>Clinical Trials Litigation</b>	<b>Kim Wilson, J.D.</b>
<b>April 6</b>	<b>Clinical Trials Billing</b>	<b>Donna Morris</b>
<b>May 12</b>	<b>Humanitarian Use Devices</b>	<b>John Falletta, M.D.</b>
<b>June 6</b>	<b>TBD</b>	<b>TBD</b>

THE CTQA LUNCH AND LEARN SERIES IS FREE AND OPEN TO THE PUBLIC – DUKE UNIVERSITY HEALTH SYSTEM AFFILIATION IS NOT REQUIRED. SEATING IS ON A FIRST COME, FIRST SERVED BASIS FOR THOSE WHO HAVE REGISTERED FOR THE SERIES.

ALL SESSIONS ARE SCHEDULED FOR 12:00-1:00 PM IN ROOM 103 OF THE BRYAN RESEARCH BUILDING (NOT THE BRYAN CENTER). **SESSIONS HAVE BEEN APPROVED FOR 1.2 NURSING CONTACT HOURS AND 1.0 CONTINUING EDUCATION UNITS.**

PLEASE REGISTER FOR THE SERIES BY E-MAILING [CTQA@MC.DUKE.EDU](mailto:CTQA@MC.DUKE.EDU)  
BRING YOUR LUNCH, THE COMPLIANCE OFFICE WILL PROVIDE DRINKS AND DESSERTS!!

**PUBLICATIONS  
Division of Neurology**

For the March edition of the NCRO Newsletter, we will be summarizing active research in the Division. Please forward to JoAnn Jones any reference citations for papers published since January 2006 prior to April 1, 2006. Thank you.